DGIdb - LOMUSTINE Drug Record

LOMUSTINE chembl:CHEMBL514 ApprovedAntineoplasticImmunotherapy

Alternate Names:

NSC-79037
CEENU
GLEOSTINE
CCNU
CCN-U
LOMUSTINE
LOMUSTINA
CEENU®
BELUSTINE
CYCLOHEXYL CHLOROETHYL NITROSOUREA
CHLOROETHYLCYCLOHEXYLNITROSOUREA
LOMUSTINUM
1-(2-CHLOROETHYL)-3-CYCLOHEXYLNITROSOUREA
1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA
N-(2-CHLOROETHYL)-N'-CYCLOHEXYL-N-NITROSOUREA
CINU
CECENU
chembl:CHEMBL514
pubchem.compound:3950
drugbank:01206
rxcui:6466
chemidplus:13010-47-4

Drug Info:

(2 More Sources)

Publications:

Erdem-Eraslan et al., 2016, Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial., Cancer Res.
Singh et al., 1983, Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells., Environ Mutagen
Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.
Kokkinakis et al., 1997, Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents., Cancer Res.
Herrlinger U et al., 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial., Lancet

LOMUSTINE ADK

Interaction Score: 5.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6317371

Sources:
NCI
LOMUSTINE ATRX

Interaction Score: 3.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23904111

Sources:
CIViC
LOMUSTINE MGMT

Interaction Score: 3.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9393761 30782343

Sources:
NCI CIViC
LOMUSTINE IDH1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Lomustine

Indication/Tumor Type glioblastoma multiforme

Response Type predicted – sensitive

PMIDs:
26762204

Sources:
JAX-CKB

NCI: LOMUSTINE

Version: 14-September-2017

Alternate Names:

C617 NCI drug code

Drug Info:

Publications:

Singh et al., 1983, Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells., Environ Mutagen

NCI: CCNU
- Version: 14-September-2017
Alternate Names:

C617 NCI drug code

Drug Info:

Publications:

Kokkinakis et al., 1997, Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents., Cancer Res.
JAX-CKB: Lomustine
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Erdem-Eraslan et al., 2016, Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial., Cancer Res.

CIViC: LOMUSTINE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Herrlinger U et al., 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial., Lancet

Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.

TTD: Lomustine
- Version: 2020.06.01
Alternate Names:

D04JPJ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL514
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

combination therapy	Bevacizumab + Lomustine
Indication/Tumor Type	glioblastoma multiforme
Response Type	predicted – sensitive

LOMUSTINE Drug Record

LOMUSTINE chembl:CHEMBL514 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

LOMUSTINE ADK

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6317371

Sources: NCI

LOMUSTINE ATRX

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23904111

Sources: CIViC

LOMUSTINE MGMT

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9393761 30782343

Sources: NCI CIViC

LOMUSTINE IDH1

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Bevacizumab + Lomustine Indication/Tumor Type glioblastoma multiforme Response Type predicted – sensitive

PMIDs: 26762204

Sources: JAX-CKB

NCI: LOMUSTINE

Alternate Names: C617 NCI drug code

Drug Info:

Publications: Singh et al., 1983, Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells., Environ Mutagen

NCI: CCNU

Alternate Names: C617 NCI drug code

Drug Info:

Publications: Kokkinakis et al., 1997, Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents., Cancer Res.

JAX-CKB: Lomustine

Alternate Names:

Drug Info:

Publications: Erdem-Eraslan et al., 2016, Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial., Cancer Res.

CIViC: LOMUSTINE

Alternate Names:

Drug Info:

TTD: Lomustine

Alternate Names: D04JPJ TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL514

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
6317371

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23904111

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
9393761 30782343

Sources:
NCI CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Lomustine

Indication/Tumor Type glioblastoma multiforme

Response Type predicted – sensitive

PMIDs:
26762204

Sources:
JAX-CKB

Alternate Names:

C617 NCI drug code

Publications:

Singh et al., 1983, Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells., Environ Mutagen

Alternate Names:

C617 NCI drug code

Publications:

Kokkinakis et al., 1997, Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents., Cancer Res.

Publications:

Erdem-Eraslan et al., 2016, Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial., Cancer Res.

Alternate Names:

D04JPJ TTD Drug ID